Magazine article Clinical Psychiatry News
Topiramate Clears Psoriasis in Mood Disorder Patients. (Study of Seven Patients)
Topiramate, an antiepileptic drug, was highly successful in the treatment of psoriasis in a small pilot study of eight individuals.
All but one of the patients responded to the treatment in the study, and, in the seven patients who did respond, scores on the Psoriasis Area and Severity Index decrease from a mean of 14.3 to 3.9 after 16 weeks of treatment, reported Dr. Ralph S. Ryback, a psychiatrist in Rockville, Md. (Br. J. Dermatol 147:130-33, 2002).
All of the subjects in the series were referred to Dr. Ryback for psychiatric consultation, but one patient whose psoriasis responded to topiramate had no diagnosable emotional problems.
The patients received topiramate in the course of treatment for bipolar disorder, depression, or other mood disorders, he said.
"Even though the series had only seven patients, the finding is very interesting because the patients did so well," said Dr. John Y.M. Koo, a professor of dermatology at the University of California, San Francisco.
"That's a fantastic result in just 4 months," according to Dr. Koo, who is also a psychiatrist.
The average dosage of the drug used was 56 mg/day, substantially below the dose normally used to treat adult epilepsy Initially, the drug was started at 25 mg/day or less in these patients and titrated up, generally by 15 mg/day or 25 mg/day every week. …